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Abstract
Background: Gualou Xiebai Decoction (GXD) is a well-known traditional Chinese recipe. It has been used to treat
cardiovascular disorders for nearly two thousand years. But there is a lack of reports on cardiac fibrosis and
underlying mechanism.
Methods: Myocardial infarction was performed by ligation of left anterior descending coronary artery (LAD)
in male Wistar rats. Rats with myocardial infarction were treated with GXD (1.14 g/kg, 4.53 g/kg) daily for
4 weeks. Cardiac function was evaluated by echocardiography. Hemodynamic parameters and infarct size
were measured in each group. Myocardial enzymes were examined by biochemical tests. Inflammatory
cytokines were assessed by ELISA, and interrelated proteins were detected by western blot.
Results: Cardiac function was significantly improved in GXD-treatment rats after myocardial infarction (MI),
which was accompanied with decreased infarct size. Administration of GXD to myocardial fibrosis rats
significantly ameliorated the activities of AST, LDH and CK-MB in serum. The increase in inflammatory
factors (TNF-α, IL-1β) were markedly reduced upon GXD treatment. Furthermore, the inflammatory
mediators (NF-κB p65, TNF-α, MCP-1) were down-regulated by GXD in the myocardial fibrosis rats.
Conclusions: Treatment with GXD improved cardiac function induced by myocardial fibrosis by inhibiting
expression of inflammatory mediators associated with NF-κB.
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Background
Gualou Xiebai Decoction (GXD), also known as
Gualou Xiebai Baijiu Decoction, is a preparation
consisting of Trichosanthes kirilowii Maxim and
Allium macrostemon Bge in a weight ratio of 2:1.
This formula is firstly described by Zhang Zhong-jing
(in the Chinese Donghan Dynasty, 3 century) in the
treatise “Jin Kui Yao Lue”. For centuries, GXD has been
widely used to treat many cardiovascular disorders,
including myocardial infarction, heart failure, and
arrhythmias [1, 2].
Myocardial fibrosis, is thought to contribute to sudden
cardiac death, ventricular tachyarrhythmias, left ven-
tricular dysfunction, and heart failure.It is characterized
by a structural rearrangement of the cardiac chamber
wall that involves cardiomyocyte hypertrophy, fibroblast
proliferation, and increased deposition of extracellular
matrix (ECM) proteins [3]. The proliferation of intersti-
tial fibroblasts and increased deposition of ECM compo-
nents results in myocardial stiffness and diastolic
dysfunction, which ultimately leads to heart failure [4].
Fibrosis typically results from activation of inflammation
and reparative pathways in response to a persistent in-
jurious stimulus. Most types of cardiac injury trigger a
local inflammatory reaction of proteases. Therefore, it is
important to examine the effect of GXD on inflamma-
tory response contributing to myocardial fibrosis.
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Our previous studies had shown that ethanol extraction
from GXD could ameliorate myocardial fibrosis by re-
duced left ventricle weight/body weight ratio, prevented
the expression of Collagen I and Collagen III, the mechan-
ism maybe involve in inhibiting the TGF-β1 signaling
pathway [5]. However, it remains unclear how GXD has
an effect on cardiac function and heart remodeling after
myocardial infarction. It is suggested that activation of in-
flammatory mediators related to NF-kappa-B (NF-κB)
could be major components of myocardial fibrosis [6].
Therefore, the aim of this study was to provide additional
evidence of its effect on alterations of cardiac function
and heart remodeling in myocardial fibrosis rats, as well




Gualou and Xiebai were identified and authenticated as
whole fruits of Trichosanthes kirilowii Maxim and dried
bulbs of Allium macrostemon Bunge by Professor Qian
Shi-hui (Jiangsu Province Academy of Traditional Chin-
ese Medicine, Nanjing, China). A voucher specimen
(2012-01-08) was deposited in the herbarium of this
academy.
Extract preparation
Gualou (Trichosanthes kirilowii Maxim) and Xiebai (Al-
lium macrostemon Bge) were mixed in a ratio of 2:1,
reaching a total weight of 4000 g. The mixture was
decocted three times under refluxing with 50 % ethanol,
each for 2 h. The solution obtained was concentrated to
dryness on a rotary vacuum evaporator, affording
1509.6 g extract (yield: 37.74 %). The main compounds
of the extract were identified by UPLC-QTOF/MS/MS
as reported previously [5].
Ethics statement
Animal experiments were performed in accordance with
the Guide for the care and Use of Laboratory Animals
published by the US National Institutes of Health (publi-
cation no. 85–23, revised 1996), and the study was ap-
proved by our Institute Animal Experimental Ethical
committee. And the performed of experiment was fit the
international, national and institutional animal experi-
ment rules. All the animals were sacrificed by anesthesia
at the end of the experiment.
Experimental animals
Male Wistar rats (n = 54) weighing 250–300 g were pur-
chased from Sino-British Sippr/BK Lab Animal Ltd.
(Shanghai, China). The rats were housed under a 12 h:
12 h light/ dark cycle, with free access to standard
rat-chow diet and tap water. Animals were allowed a
1-week acclimatization period prior to the experimental
protocol.
Myocardial infarction model
Rats were intraperitoneally anesthetized with 10 %
chloral hydrate (300 mg/kg), intubated with polyethylene
tube and ventilated with an automatic breathing appar-
atus (Shanghai Alcott Biotech CO., LTD., China) at a re-
spiratory rate of 70 breaths/min and a tidal volume of
2.0 ml. The heart was rapidly exteriorized. A 6–0 silk su-
ture was placed through the myocardium into the an-
terolateral left ventricular wall around the left anterior
descending coronary artery (LAD) approximately 2–
3 mm distal from its origin. The vessel was permanently
ligated. The ligation was confirmed successfully when
the anterior wall of the left ventricle turned pale. After
surgery, the chest was closed and the animals were
allowed to recover. A similar surgery procedure was per-
formed without LAD ligation in 8 rats (Sham group) [7].
Ten rats died during the 24-h postoperative period be-
cause of acute pumps failure or lethal arrhythmias. 36
rats with myocardial infarction (MI) survived.
The 36 rats with MI were randomly divided into three
groups of 12 rats, each divided by treatment with high-
or low-dose GXD, or distilled water: GXD rats received
low doses of GXD (1.14 g/kg, oral gavage), or high doses
(4.53 g/kg, oral gavage), and MI rats received distilled
water as did Sham rats. These doses were selected on
the basis of human clinical dosage and our earlier stud-
ied of the cardio protective effect of GXD; the appropri-
ate dose for the GXD extract was calculated according
to the yield [8, 9]. Treatment with GXD was continued
further for 4 weeks once daily at the same time.
Echocardiographic measure of cardiac function
To evaluate LV (left ventricular) function, transthoracic
echocardiography was performed with a Vevo 2100 instru-
ment (VisualSonics) at the end of the study [10]. Under
general anesthetized with chloral hydrate, animals were im-
aged using a 40-MHZ linear array transducer. M-mode and
two-dimensional parasternal short-axis scans at the level of
the papillary muscles were used to assess changes in LV
end-diastolic inner diameter (LVID;d), LV end-systolic
inner diameter (LVID;s), LV posterior wall thickness in
end-diastole (LVWP;d) and in end-systole (LVPW;s) and in-
terventricular septal diastolic wall thickness (IVS; d) and
systolic wall thickness (IVS;s). To assess LV systolic func-
tion, fractional shortening (FS) and ejection fraction (EF)
were calculated as follows: FS = [(LVID;d - LVID;s)/
LVID;d] × 100 %, EF = [(LVID;d3-LVID;s3)/LVID;d] ×
100 %.LV end- diastolic volume (LVEDV) and end-systolic
volume (LVESV) were acquired by 7/(2.4 + LVID; d) ×
LVID; d3 and 7/(2.4 + LVID; s) × LVID; s3, respectively.
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Hemodynamic measurement
To determine the heart hemodynamic function, parame-
ters were measured in closed-chest anesthetized rats
[11]. Animals were anesthetized with chloral hydrate
and trachea was intubated to facilitate breathing. Body
temperature was maintained at 37 to 38 °C. A midline
incision was made to expose the right common carotid
artery. A catheter tip pressure transducer (Mikrotip
1.4 F, Millar Instrument, Houston, TX, USA) was then
inserted into the right carotid artery and advanced to
the LV under guidance of the pressure signal and fixed
in position. The heart rate, systolic and diastolic pres-
sure, LV pressure, and the rate of pressure development
(maximal positive, +dP/dt; maximal negative, −dP/dt)
were recorded at a rate of 500 HZ through a Biopac
MP100 data acquisition unit (Biopac systems Inc.,
Goleta, CA, USA). A period of approximately 20 min
was allowed for stabilization of cardiovascular parame-
ters before the hemodynamic data were recorded. An 8 s
recording was analyzed with AcqKnowledge software for
each animal.
Myocardial enzymes and inflammatory cytokines
measurement in serum
After hemodynamic measurements, the blood samples
were collected from the abdominal artery and the serum
was separated. Creatine kinase-MB (CK-MB), aspartate
aminotransferase (AST) and lactate dehydrogenase
(LDH) were determined by auto biochemical analysis
system (Roche Modular DP, Germany). Interleukin-
1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α)
in serum were determined by enzyme-linked immuno-
sorbent assay (ELISA) kits (R&D ELISA Kit, USA) fol-
lowing the manufacturer’s instructions.
Infarct size evaluation
To evaluate the infarct size, the hearts were removed
and dissected. Cardiac tissue samples were fixed in a
10 % formaldehyde solution for 48 h and stained with
hematoxylin and eosin according to the previously de-
scribed method [12]. The infarction size of left ventricle
was determined in sections 5 to 6 mm from the apex, since
the values in this region correspond to the mean of the
values obtained from sections of the entire heart. The
lengths of the infracted and viable myocardial for both the
endocardial and epicardial circumferences were deter-
mined by planimetry [13]. Infarction size was expressed as
a percentage of the sum of endocardial and epicardial
infracted ventricular lengths to the sum of total (infracted
and viable myocardial) endocardial and epicardial ven-
tricular circumferences. Slides were observed with the
Zessi Axioskop 2 microscope and digitally photographed,
and analyzed using Image-Pro Plus 6.0 (Media Cybernetics
Inc., Baltimore, MD, USA).
Western blot analysis
Nuclear protein was extracted by Nuclear Extraction Kit
(Millipore) and total cellular protein was extracted from
frozen tissue by RIPA buffer containing 1 mM PMSF. All
protein extractions were adjusted to equal contraction
using BCA assay. Equal amounts (40 μg/lane) of each sam-
ple were separated on polyacrylamide gel electrophoresis
and transferred by electrophoresis onto nitrocellulose
membrane (Millipore). Following washing and blocking,
the membrane was incubated overnight at 4 °C with pri-
mary antibody against NF-κB p65 (Santa Cruze, 1:1000),
TNF-α(Santa Cruze, 1:1000), MCP-1(Santa Cruze, 1:1000).
After washing, the membrane was incubated with second-
ary antibody at 37 °C for 1 h. Bands were visualized by en-
hanced chemiluminescence kit (Pierce, Rockford, IL, USA).
Target proteins levels were normalized byGAPDH.
Statistical analysis
Data are expressed as mean ± SD. All statistical analyses
were performed using SPSS software (Version 11.5, SPSS
Inc., Chicago, IL, USA). Statistical significance involving
multiple groups was performed using a one-way analysis
of variance (ANOVA). Differences were considered to be
significant at P < 0.05.
Results
GXD improved cardiac function caused by cardiac fibrosis
Cardiac function is known to deteriorate at later stages
after MI and is, in fact, becoming an increasingly more
frequent cause of cardiac failure in post-MI survivors.
To determine whether GXD transfer improved cardiac
performance, we performed echocardiography four
weeks after MI (Fig. 1). LVID;d and LVID;s were signifi-
cantly increased in MI rats (P < 0.01, Fig. 1b, c) relative
to sham rats, and a marker decrease in low- and high-
dose groups (P < 0.01, vs MI group). IVS and LVPW at
both systole and diastole exhibited lower in MI group
than Sham group (P < 0.01, Fig. 1d, e, f, g), and 1.14 g/kg
and 4.53 g/kg groups showed higher IVS and LVPW
than that of MI group (P < 0.05 ~ 0.01), which indicated
that GXD could inhibit interventricular septal hyper-
trophy. FS and EF, the index of left ventricular systolic
function, were significantly decreased in MI group, these
changes were attenuated when MI rats were treated with
GXD (P < 0.05 ~ 0.01, vs MI group, Fig. 1h, i). Further-
more, LVEDV and LVESV were greater in MI group
compared with Sham group respectively (P < 0.01, Fig. 1j,
k), and they were smaller in low- and high-dose groups
(P < 0.01, vs MI group). These data suggest that GXD
could attenuate myocardial dysfunction induced by myo-
cardial fibrosis. To further assess cardiac function,
hemodynamic parameters were analyzed four weeks
after GXD-treated. After MI, LVEDP was increased,
while HR, SBP, DBP, LVSP were decreased in MI rats
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when compared with sham-operated rats (P < 0.01,
Table 1). Treatment with GXD almost restored all of
them to the near normal levels (P < 0.05 ~ 0.01, vs MI
group). There were significant decrease in ± dP/dt be-
tween the Sham group and MI group (P < 0.01, Table 1).
However, the decrease in ± dP/dt in MI rats were signifi-
cantly increased by GXD treatment (P < 0.05 ~ 0.01, vs
MI group). The significant changes of SBP, DBP, LVSP,
LVEDP and ± dP/dt indicated that GXD could improve
cardiac function of post-infarction.
GXD inhibited myocardial injury and inflammation
Myocardial enzymes CK-MB, AST, LDH are biochemical
indicators of myocardial injury. As compared with Sham
group, the levels of all three enzymes were significantly
elevated in the MI group (P < 0.01, vs Sham group,
Fig. 2a, b). GXD protected MI rats against cardiac injury,
which was evidenced by decreased myocardial enzymes
in GXD-treated group (P < 0.05 ~ 0.01, vs MI group).
Moreover, the inflammatory factors IL-1βand TNF-
αwere also increased in MI group compared to Sham
group (P < 0.01, Fig. 2c). By contrast, lower levels of IL-
1βand TNF-α were found in GXD-treated group com-
pared to MI group (P < 0.05 ~ 0.01).
GXD reduced infarct size after MI
To substantiate the effect of GXD in LV remodeling
after MI, we analyzed infarct size. Quantitative
Fig. 1 Effect of GXD on echocardiographical parameters in MI rats. a Representative echocardiography pictures of M mode images. The quantitative
data of (b) LV end-diastolic inner diameter (LVID; d); (c) LV end-systolic inner diameter (LVID; s); (d) LV posterior wall thickness in end-diastole (LVWP; d);
(e) LV posterior wall thickness in end-systole (LVPW; s); (f) interventricular septal diastolic wall thickness (IVS; d); (g) interventricular septal systolic wall
thickness (IVS; s); (h) fractional shortening (FS); (i)ejection fraction (EF); (j) LV end- diastolic volume (LVEDV); (k)end-systolic volume (LVESV). Results are
expressed as mean ± S.D. (n = 8 for Sham group and n = 12 for other groups). △△P < 0.01 vs sham group; *P < 0.05, **P < 0.01 vs MI group
Table 1 Effect of GXD on hemodynamic parameters and cardiac function induced by coronary artery ligation
sham MI GXDL GXDH
HR(beats/min) 359.6 ± 42.3 259.8 ± 29.5△△ 306.0 ± 55.4* 333.7 ± 57.2**
SBP(mmHg) 107.1 ± 10.1 82.9 ± 7.7△△ 88.4 ± 7.3 99.1 ± 10.2**
DBP(mmHg) 69.93 ± 10.47 56.48 ± 8.07△△ 62.59 ± 5.26* 67.26 ± 11.65*
+LV dp/dtmax(mmHg/s) 5287.03 ± 1247.53 3312.07 ± 859.48
△△ 4062.42 ± 623.19* 4752.61 ± 930.10**
-LV dp/dtmin(mmHg/s) 4099.12 ± 759.61 3005.07 ± 517.25
△△ 3357.75 ± 774.67 3822.46 ± 905.39*
LVSP(mmHg) 120.99 ± 10.15 88.94 ± 6.86△△ 95.70 ± 7.57* 105.24 ± 9.85**
LVEDP(mmHg) −4.57 ± 1.71 5.72 ± 1.44△△ 2.69 ± 0.88** −0.98 ± 1.70**
Values are expressed as the mean ± S.D. (n = 8 for Sham group and n = 12 for other groups). HR heart rate, SBP systolic blood pressure, DBP diastolic pressure, ±LV
dp/dtmax the maximal rates of increase and decrease of left ventricle pressure development, LVSP left ventricular systolic pressure, LVEDP left ventrilcel end dilated
pressure. △△P < 0.01 vs sham group; *P < 0.05, **P < 0.01 vs MI group
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evaluation of infarct size revealed that there was sig-
nificant decrease in infarct size in MI group com-
pared with the sham group (P < 0.01; Fig. 3). This
decrease in infarct size was prevented by treatment
with GXD (P <0.05 ~ 0.01, vs MI group).
GXD inhibited inflammatory mediators in the MI heart to
prevent myocardial fibrosis
The NF-κB family plays an important role in inflamma-
tory responses by promoting the expression of proin-
flammatory factors, we investigated the NF-κB p65 by
Fig. 2 Effect of GXD on myocardial injury and inflammation factors. The quantitative data of (a) aspartate aminotransferase (AST);
(b) lactate dehydrogenase (LDH) and Creatine kinase-MB (CK-MB); (c) tumor necrosis factor-alpha (TNF-α) and Interleukin-1beta (IL-1β).
Results are expressed as mean ± S.D. (n = 8 for Sham group and n = 12 for other groups). △△P < 0.01 vs sham group; *P < 0.05, **P < 0.01
vs MI group
Fig. 3 Effect of GXD on infarct size. a Representative microphotographs (×100) stained with hematoxylin and eosin (H/E). b Histogram of the
effect of GXD on infarct size. Results are expressed as mean ± S.D. (n = 8 for Sham group and n = 12 for other groups). *P < 0.05, **P < 0.01 vs
MI group
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which GXD attenuates myocardial fibrosis. As shown in
Fig. 4, the protein levels of p65 protein in the nucleus
was significantly increased in the MI heart (P < 0.01 vs
Sham group) but reduced in the GXD-treated MI heart
(P < 0.01, vs MI group). In line with the alteration of the
NF-κB signaling, NF-κB-targeted cytokines, such as
TNF-α and MCP-1 expression, were significantly ele-
vated in the MI heart. However, their levels were much
lower in the heart of GXD-treated MI hearts.
Discussion
Generally, cardiac function requires the orchestration of
multiple mechanical and biological factors within the
myocardial microenvironment. The cellular matrix pro-
vides a structural foundation for the myocytes, fibro-
blasts, and endothelial cells to build an architectural
network and provides an environment for cell signaling,
cell-cell interactions, etc. [14, 15]. Excessive myocardial
fibrosis is an important pathophysiological process that
contributes to diastolic and eventually systolic dysfunc-
tion by increasing myocardial stiffness and reducing
pumping capacity. The amount of collagen present in
the myocardium has also been reported to represent the
most significant factor related to echocardiographic
demonstration of diastolic dysfunction in hypertensive
heart disease [16, 17]. In this report, we have demon-
strated that GXD could attenuate LV systolic and dia-
stolic functional echocardiographic and hemodynamic
parameters induced by myocardial fibrosis.
Fibrosis typically results from activation of inflamma-
tory and reparative pathways in response to a persistent
injurious stimulus [18]. Most types of cardiac injury trig-
ger a local inflammatory reaction inducing upregulation
of cytokines and fibrogenic growth factors and promot-
ing activation of proteases [19]. Myocardial infarction re-
sults in cardiomyocyte necrosis and induces an intense
inflammatory response. The cardiac repair process can
be divided into three overlapping phases: the inflammatory
phase, the proliferative phase and the maturation phase.
During the inflammatory phase, cardiomyocyte death and
hypoxia result in free radical generation, initiation of the
complement cascade, and activation of NF-κB and mono-
cyte chemoattractant protein-1 (MCP-1)/CCL-2 signaling
pathway [19, 20]. Both macrophage and T cells may release
cytokines that can act on cardiac resident cells during the
inflammation processes of infarct healing. Among the re-
lease cytokines are interleukins (ILs), tumor necrosis fac-
tors (TNFs), interferons (IFNs), platelet-derived growth
factor (PDGFs), fibroblast growth factors (FGFs), trans-
forming growth factor (TGF)-βs, etc.[21].
NF-κB, which regulates inflammatory and immune pro-
cesses, is a ubiquitous transcription factor. Members of
NF-κB family (p50, p52, p65, c-Rel and Rel B) form homo
or heterodimers (most commonly p50/p65, p50/p50, or
p65/p65) that are bound to inhibitory IκB proteins in the
cytosol [22, 23]. Once activated, NF-κB translocates into
the nucleus from the cytosol, then binds to the consensus
sequence on promoter or enhancer regions of related
genes and regulates gene transcription [24]. NF-κB plays
Fig. 4 Effect of GXD on inflammatory mediators expression. a Representative Western blotting analysis of myocardial fibrosis tissue. The ratios of
various proteins to GAPDH are presented in panels b, c, d. Protein levels were calculated by densitometry. Results are expressed as mean ± S.D.
(n = 3). △△P < 0.01 vs sham group; **P < 0.01 vs MI group
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an important role in myocardial fibrosis. NF-κB contrib-
utes to myocardial fibrosis pathogenesis because it regu-
lates genes/proteins important for disease progression,
including cytokines (e.g., TNF-α), interleukins (e.g.,IL-1β).
TGF-β/Smads signaling are markedly induced in the
infracted myocardium and through their potent effects are
capable of playing a central role in infarct healing, cardiac
repair and left ventricular remodeling. TGF-β1 overexpress-
ing mice exhibited significant cardiac hypertrophy accom-
panied by interstitial fibrosis [25]. It is now well accepted
that inactivation of Smad2/3 by overexpression Smad7 in-
hibits NF-κB –dependent inflammatory response by indu-
cing inhibitor of NF-κBα expression. So, the interaction
between the TGF-β/Smads and NF-κB signaling pathways
may be important in cardiac inflammation [26, 27]. Previ-
ously, we have showed that GXD ameliorated heart injury
and protected rats from myocardial fibrosis, which may be
related to inhibiting the TGF-β1 signaling pathway by
down-regulating expressions of Smad2/3 whereas improv-
ing Smad7 expression. And in this paper, we found that
GXD could down-regulate NF-κB and NF-κB-targeted cy-
tokines, such as TNF-α and MCP-1 expression. The further
studies are necessary to elucidate the effect of GXD on
cross-talk of TGF-β and NF-κB signaling.
Conclusions
We demonstrated that myocardial fibrosis induced by li-
gating the left anterior descending coronary artery was
clearly prevented by treatment with GXD. Cardiac func-
tion was significantly improved in GXD-treatment rats
after MI (myocardial infarction). From molecular ana-
lyses, we concluded that the effect of GXD were
dependent on inhibition of the inflammatory response
through the NF-κB pathway. It could dose-dependently
improve the cardiac function after MI by downregula-
tion of NF-κB expression, and suppressing NF-κB-
targeted cytokines, such as TNF-α and MCP-1 produc-
tion. However, the effect of GXD on restraining myocar-
dial fibrosis still needs further investigation.
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